Following Earnings And Shelf Filing Is Celldex Therapeutics (CLDX) Undervalued?

Celldex Therapeutics (CLDX) just dropped third quarter results and filed a universal shelf registration, a double update that put its ongoing losses and future funding options in sharper focus for investors.

Those earnings and the universal shelf registration came alongside mixed share performance, with a 1-day share price return of 1.05% and a 30-day share price gain of 3.57%, but a 90-day share price drop of 31.28% and a 5-year total shareholder return decline of 32.92%. This leaves Celldex Therapeutics looking like a story where near term momentum has faded, even as the 1-year total shareholder return of 12.84% remains positive.

Spot 20 high quality undiscovered gems that, like Celldex Therapeutics after its earnings and shelf registration news, sit at the crossroads of funding needs and potential pipeline progress.

Celldex Therapeutics trades at a sharp discount to analyst targets, with the share price far below some valuation estimates. Is that gap a warning sign, or a potential pricing mismatch that the numbers can clarify next?

Most Popular Narrative: 2% Undervalued

Celldex Therapeutics closed at $28.83 against a narrative fair value of $29.51, a small gap that still leaves plenty riding on barzolvolimab according to the bearish analyst Narrative on Simply Wall St, which leans on the most pessimistic price targets and forecasts.

The recent failure of barzolvolimab in prurigo nodularis despite profound mast cell depletion signals that indication selection is less straightforward than early enthusiasm suggested. This could limit future expansion opportunities for Celldex Therapeutics and reduce the long term revenue and earnings potential of the broader mast cell platform.

See why 1 investors see Celldex Therapeutics as 2% undervalued.

Result: Fair Value of $29.51 (UNDERVALUED)

Still, if barzolvolimab’s real world safety profile stays supportive and CDX-622 confirms its early signal, the bearish Celldex Therapeutics narrative could be challenged quickly.

Find out about the key risks to this Celldex Therapeutics narrative.

Another View: SWS DCF Flags a Very Different Fair Value

The analyst narrative for Celldex Therapeutics leans on a $29.51 fair value, yet the SWS DCF model paints a very different picture. On that future cash flow view, the shares at $28.83 sit well above an estimated value of $5.24. That gap raises a simple question: Which story do you trust more, the pipeline focus or the cash flow math?

Look into how the SWS DCF model arrives at its fair value.

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Celldex Therapeutics for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 32 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Sentiment on Celldex Therapeutics is clearly split, with real concerns alongside genuine optimism about the pipeline and valuation story. Act quickly and check the underlying data for yourself, starting with the 1 key reward and 3 important warning signs.

Looking for more investment ideas beyond Celldex Therapeutics?

If Celldex Therapeutics has you rethinking risk, return, and timing, do not stop here. Broaden your watchlist with a few targeted filters that surface opportunities you might otherwise miss.

• Target potential mispricings by scanning a focused set of quality companies using the 32 high quality undervalued stocks.
• Strengthen your downside protection by zeroing in on businesses backed by robust finances through the list of solid balance sheet and fundamentals (24 results).
• Balance risk and reward by reviewing a 31 resilient stocks with low risk scores, which can complement higher volatility positions like Celldex Therapeutics.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com